Berberine
Both can lower glucose and may increase hypoglycemia risk.
Recommendation: Avoid aggressive stacking and monitor glucose.
Herb ·Emerging evidence ·Reviewed May 2026
Bitter melon is a tropical fruit used traditionally for blood sugar support and studied in type 2 diabetes. Human results are mixed, and preparations vary widely in charantin, vicine, and insulin-like peptide content. It can meaningfully lower glucose in susceptible people, so medication users should treat it as clinically active.
The bottom line
Evidence rating emerging. Most-documented uses: may modestly lower fasting glucose, may reduce postprandial glucose response, traditional support for insulin sensitivity. 3 sources indexed (2011–2013), with 3 interaction records on file.
Core mechanism
Bitter melon contains charantin, cucurbitane triterpenoids, lectins, and insulin-like peptides that may enhance glucose uptake, inhibit intestinal carbohydrate digestion, and activate AMPK-related pathways. Some extracts affect adipocyte and muscle glucose transport in preclinical models. Seed constituents such as vicine contribute to safety concerns, especially in pregnancy and G6PD deficiency.1,2
Take with meals for glucose-related use and to reduce GI upset. Avoid seed-heavy or poorly characterized products.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Standardized bitter melon extract capsule.
Standardized extracts cost more; juices and powders are cheaper but less predictable. Updated 2026-06-04.
What to test, the optimal window inside the conventional range, and how long a response takes.
May modestly lower fasting glucose and HbA1c in responders.2,3
Check fasting glucose at baseline and after a consistent trial; monitor more closely if using glucose-lowering medication.
May modestly lower HbA1c when glycemic control improves.1
HbA1c reflects roughly 2-3 months of glycemia and should not be interpreted alone in anemia or altered red cell turnover.
Where this appears in the symptom-to-supplement map, ranked by relevance.
May inhibit carbohydrate digestion and support glucose uptake.3,2
Use glucose monitoring to verify response.
May influence insulin-like and AMPK-related pathways.2,3
Evidence is mixed.
Bitter compounds may support meal structure but direct craving evidence is limited.2,3
Not a primary craving intervention.
Both can lower glucose and may increase hypoglycemia risk.
Recommendation: Avoid aggressive stacking and monitor glucose.
Combined use may intensify glucose-lowering effects.
Recommendation: Monitor fasting and post-meal glucose when starting or increasing doses.
Both can cause GI upset, and concentrated extracts may add liver-safety uncertainty in susceptible people.
Recommendation: Use lower doses and avoid in liver disease unless clinician-directed.
Numbered references. Citations throughout the page link here.
Available trials were small and did not provide high-quality evidence of durable glycemic benefit.
Bitter melon at 2,000 mg/day showed some fructosamine reduction but was less effective than metformin.
Mechanistic data support glucose uptake and carbohydrate digestion effects, while human evidence remains inconsistent.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.